The latest price target for Health Catalyst (NASDAQ:HCAT) was reported by Citigroup on January 9, 2026. The analyst firm set a price target for $2.75 expecting HCAT to rise to within 12 months (a possible 47.85% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Health Catalyst (NASDAQ:HCAT) was provided by Citigroup, and Health Catalyst maintained their neutral rating.

The last upgrade for Health Catalyst Inc happened on January 8, 2025 when Keybanc raised their price target to $9. Keybanc previously had a sector weight for Health Catalyst Inc.

The last downgrade for Health Catalyst Inc happened on August 27, 2025 when Piper Sandler changed their price target from $8 to $4 for Health Catalyst Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Health Catalyst, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Health Catalyst was filed on January 9, 2026 so you should expect the next rating to be made available sometime around January 9, 2027.

While ratings are subjective and will change, the latest Health Catalyst (HCAT) rating was a maintained with a price target of $3.25 to $2.75. The current price Health Catalyst (HCAT) is trading at is $1.86, which is out of the analyst’s predicted range.